Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from HIMS

Hims & Hers Bets Big on GLP-1 Drugs, But Investors Want Profits Now

Hims & Hers delivered a sharp earnings miss as GLP-1 and international expansion costs surged. Investors now face a classic tradeoff between near-term margins and long-term growth.

Barchart

Hims & Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recovery?

Hims & Hers Health posted a Q1 FY2026 double miss, with an EPS loss of $0.40 and revenue of $608.1 million, sending shares down more than 12% after hours.

MarketBeat

Hims & Hers Health Q1 Earnings Call Highlights

Hims & Hers Health (NYSE:HIMS) reported first-quarter 2026 revenue growth and raised its full-year revenue outlook, while executives said a strategic shift in the company’s weight-loss business is creating short-term margin pressure and volatility in GAAP results. On the company’s earnings call

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

Hims earnings today: Why Hims & Hers Health stock dropped despite raising revenue forecast - here's what investors need to know

Hims stock after Hims & Hers earnings: Hims & Hers Health shares dropped significantly after reporting a surprise first-quarter loss and revenue below expectations. Despite these weak results, the company raised its full-year revenue outlook and projected strong second-quarter revenue, as it navigates regulatory scrutiny around weight-loss drugs.

The Economic Times

What the FDA's Latest Proposal Means for Lilly, Novo, and Hims

The FDA's latest proposal would be a win for Eli Lilly and Novo Nordisk, while Hims & Hers Health would also garner indirect benefits.

MarketBeat

Amazon Takes a Bite Out of Hims: What Its GLP-1 Entrance Means

Amazon is stepping into the GLP-1 arena, with the consumer giant positioning itself as a competitor to Hims & Hers Health. Hims may have a problem on its hands.

MarketBeat

Should You Buy HIMS Stock Following Friday's Rally?

Hims & Hers stock rallied on Friday on a major regulatory update and bullish analyst note. Here’s how high HIMS shares could realistically fly through the end of 2026.

Barchart

Read news from The Economist, FT, and more,
with one subscription

RFK Jr.'s peptide push could become next wellness boom

The heavily touted but loosely regulated proteins could fuel the kind of boom we've seen with weight-loss drugs.

Axios

RFK Jr. Just Gave Hims & Hers Stock a Jolt. Should You Chase the Rally Here?

Hims & Hers stock rallies as RFK Jr. says FDA may remove restrictions on certain peptides. But HIMS shares remain unattractive to own in 2026.

Barchart

3 Sectors to Buy While They're Down and 1 to Walk Away From

Jeff Clark and Andy Swan share three beaten-down sectors with contrarian upside and one popular sector to avoid, plus specific stock picks in financials, healthcare, and software.

MarketBeat

MarketBeat Week in Review – 03/09 - 03/13

Stocks moved higher this week despite uncertainty over the Iran conflict and oil prices; economic indicators point to no change in interest rates next week

MarketBeat

Should You Chase the Rally in Hims & Hers Stock Today?

Hims & Hers shares extend gains as Eli Lilly warns impurity it discovered in compounded versions of its weight-loss drug has health implications. Here’s why HIMS stock isn’t worth owning here.

Barchart

Patience Pays: Hims & Hers Surges on News of Novo Nordisk Deal

Hims & Hers shares surged 46% after partnering with Novo Nordisk to offer FDA-approved Ozempic and Wegovy, moving away from compounded GLP-1 alternatives.

MarketBeat

Novo Nordisk and Hims & Hers Turn Patent Dispute Into Business Opportunity

Novo Nordisk drops its lawsuit against Hims & Hers as the companies partner to offer FDA-approved Wegovy and Ozempic through the telehealth platform.

International Business Times

Get all your
news in one place.

100's of premium titles.
One news app.

Kiplinger

Stocks Recover as Oil Retreats From $119: Stock Market Today

How high the price of crude oil rises and how long it stays there are critical questions for market participants and policymakers alike.

Barchart

Hims & Hers Stock Is Challenging Its 50-Day Moving Average. Should You Bet on a Turnaround Here?

Hims & Hers shares soared as Novo Nordisk dropped its GLP-1 lawsuit. But there’s reason to still sell HIMS stock today. Find out more!

The Independent UK

Novo Nordisk drops lawsuit over weight loss medications, enters collaboration with online pharmacy

The news sent shares of Hims & Hers Health Inc. soaring by more than 40% in Monday morning trading

MarketBeat

MarketBeat Week in Review – 02/23 - 02/27

Technology stocks continue to be under pressure, and is flowing into defensive assets; investors should expect more volatility, which can create opportunities

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

Hims & Hers in Free Fall: Why Analysts See Nearly 150% Upside

HIMS is down 48% in the past month following a Novo Nordisk lawsuit. But, analysts expect record revenue when the company reports earnings this month.

Barchart

As Hims & Hers Gets Hit With Major Wegovy Loss, Should You Buy the Dip in Deeply Oversold HIMS Stock?

Hims & Hers shares crater as Novo Nordisk files a lawsuit against the telehealth firm. BofA analysts see significant further downside in HIMS stock.

The Independent UK

Hims & Hers drops plan for knockoff of Novo Nordisk's new Wegovy weight loss pill

Telehealth company Hims & Hers dropped its plan to offer a knockoff version of the weight-loss pill Wegovy on Saturday — two days after it announced the new drug

MarketBeat

Eli Lilly Booms, Then Busts: Stellar Guidance vs Hims Undercut

Investors had little time to celebrate Eli Lilly's huge post-earnings gain. While Hims & Hers Health knocked shares down, LLY remains a healthcare stalwart.

Euronews

US health company launches weight-loss pill that Novo Nordisk calls an 'untested knockoff'

The American telehealth company announced the launch of a compounded weight-loss pill for €41, drawing criticism from Novo Nordisk, the Danish company behind the weight-loss drug Wegovy, which called the product an “untested knockoff.”

The Independent UK

Hims & Hers launches copy of Wegovy pill, prompting legal threats from drugmaker Novo Nordisk

Telehealth company Hims & Hers is launching a cheaper, off-brand version of the blockbuster weight loss pill Wegovy

Benzinga

What's Going On With Shares Of Hims & Hers Health Thursday?

Shares of Hims Hers Health, Inc. (NASDAQ:HIMS) are trending Thursday morning. The San Francisco-based telehealth company announced an international expansion.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.